Recursion Pharmaceuticals (RXRX) Non-Current Debt (2020 - 2026)

Recursion Pharmaceuticals' Non-Current Debt history runs 7 years deep, the most recent figure standing at $7.2 million for Q1 2026.

• Quarterly Non-Current Debt fell 56.34% year-over-year to $7.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (down 56.34% YoY) and the FY2025 annual result came in at $9.6 million, down 49.72% from the prior year.
• Non-Current Debt was $7.2 million for Q1 2026 at Recursion Pharmaceuticals, down from $9.6 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $22.9 million in Q2 2024 and bottomed at $536000.0 in Q4 2022.
• A 5-year average of $8.1 million and a median of $4.2 million in 2023 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2022 — Non-Current Debt plunged 93.78% — and 2024, when it surged 1884.5%.
• Recursion Pharmaceuticals' Non-Current Debt stood at $536000.0 in 2022, then jumped by 105.41% to $1.1 million in 2023, then soared by 1627.7% to $19.0 million in 2024, then tumbled by 49.72% to $9.6 million in 2025, then retreated by 24.92% to $7.2 million in 2026.
• Business Quant data shows RXRX's Non-Current Debt at $7.2 million in Q1 2026, $9.6 million in Q4 2025, and $11.9 million in Q3 2025.